Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
Launched by GRANDPHARMA (CHINA) CO., LTD. · Nov 26, 2024
Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. age ≥ 18 years old;
- • 2. confirmed diagnosis of HCC
- • 3. treated with yttrium-90 during 2023.1.1 - 2024.6.30 and assessed at least once for tumor response within 6 months following treatment
- Exclusion Criteria:
- • no formal exclusion criteria in a real-world study
About Grandpharma (China) Co., Ltd.
Grandpharma (China) Co., Ltd. is a leading biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapeutics across various therapeutic areas. Established with a commitment to enhancing global health, Grandpharma leverages advanced technologies and a robust pipeline to address unmet medical needs. The company emphasizes quality and compliance throughout its operations, aiming to deliver safe and effective solutions to patients worldwide. With a strong focus on clinical research and collaboration, Grandpharma is poised to make significant contributions to the advancement of healthcare both in China and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Beijing, , China
Shanghai, , China
Jinan, Guangdong, China
Xi'an, Guangxi, China
Xi'an, Shanxi, China
Patients applied
Trial Officials
Xiaobin Feng, MD
Principal Investigator
Beijing Tsinghua Changgeng Hospital
Kangshun Zhu, MD
Principal Investigator
Second Affiliated Hospital of Guangzhou Medical University
Yefa Yang, MD
Principal Investigator
The Third Affiliated Hospital of Naval Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported